Concord Biotech Limited (CONCORDBIO.NS)
INR 1653.85
(3.01%)
INR 1653.85
(3.01%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.98 Billion INR | 19.2% |
| 2022 | 8.53 Billion INR | 20.43% |
| 2021 | 7.08 Billion INR | 17.28% |
| 2020 | 6.04 Billion INR | 17.9% |
| 2019 | 5.12 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.15 Billion INR | -32.34% |
| 2023 Q2 | 2.62 Billion INR | 34.66% |
| 2023 Q4 | 3.18 Billion INR | 32.46% |
| 2023 Q3 | 2.4 Billion INR | -8.21% |
| 2023 FY | 10.16 Billion INR | 19.2% |
| 2023 Q1 | 1.94 Billion INR | -22.08% |
| 2022 Q3 | 2.4 Billion INR | 51.47% |
| 2022 FY | 8.53 Billion INR | 20.43% |
| 2022 Q4 | 2.5 Billion INR | 3.89% |
| 2022 Q2 | 1.58 Billion INR | 0.0% |
| 2021 FY | 7.08 Billion INR | 17.28% |
| 2020 FY | 6.04 Billion INR | 17.9% |
| 2019 FY | 5.12 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Biocon Limited | 147.55 Billion INR | 93.236% |
| Blue Jet Healthcare Limited | 7.11 Billion INR | -40.256% |
| Dishman Carbogen Amcis Limited | 26.15 Billion INR | 61.845% |
| Jubilant Ingrevia Limited | 41 Billion INR | 75.66% |
| Lyka Labs Limited | 1.05 Billion INR | -849.335% |
| Panacea Biotec Limited | 5.59 Billion INR | -78.489% |
| Piramal Pharma Limited | 81.71 Billion INR | 87.786% |
| SMS Lifesciences India Limited | 3.05 Billion INR | -226.207% |
| Supriya Lifescience Limited | 5.7 Billion INR | -74.984% |
| Syngene International Limited | 34.88 Billion INR | 71.391% |
| TAKE Solutions Limited | 656.08 Million INR | -1421.243% |
| Zota Health Care Limited | 1.8 Billion INR | -452.976% |